WHO Sounds Alert Over Severe Lack of Weight-Loss Injections
Under one in 10 individuals that would benefit from obesity jabs like Wegovy are able to get them, caution the global health agency as it releases its first advice on the therapies.
With more than one billion individuals worldwide currently classified as obese, it is urging more widespread and fairer access to these injectable treatments.
Based on forecasts, more than two billion are projected to be living with obesity by 2030 without intervention.
"The new guidance recognises that excess weight is a lifelong illness that can be managed with holistic and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major hurdles to broad availability to the treatments that can help people shift considerable body mass, says the agency.
Skinny Jab Scarcity
Despite the current most optimistic scenario, the production of GLP-1 therapies could only cover around 100 million people – less than 10% of the global need, as stated by the health organization.
The guideline calls on countries and companies to widen access, via strategies including patent sharing.
The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Drugs Function
GLP-1 drugs replicate a natural hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so people consume fewer calories.
Individuals typically begin shedding pounds after several weeks of commencing the weekly injections.
Studies points to users may regain a significant portion after a year of discontinuing the treatment, when their normal hunger resume.
Being carrying excess weight elevates your likelihood for developing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.
Excess weight concerns people in all nations and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
